Isochem brings custom manufacturing capabilities to CPhI Worldwide
Press Release | ISOCHEM S.A.S.
SEPTEMBER 30, 2016
Vert-Le-Petit, France: – Fine chemicals and active ingredients specialist CMO Isochem will field a strong suite of attractions when it exhibits at CPhI Worldwide in Barcelona in October.
In particular, Isochem will be able to present visitors to its stand 3A78in Hall 3 at Fira de Barcelona, with a whole portfolio of impressive capabilities.
“There are at least five good reasons to come and visit us,” commented Isochem VP of Sales and Business Development, Amélie Arboré, who will be part of the stand team.
“These include custom manufacturing of cGMP intermediates, a very strong product list of intermediates and generic APIs, Vitamin E TPGS for innovative drug formulation and a wide range of Aminoacid-NCA monomers for preparation of well-defined polypeptides by ring opening polymerization,” said Ms. Arboré.
Custom synthesis emphasis
“All these are the result of investments in ramping up our teams and capabilities in R&D and project management and a conscious refocusing on our pharmaceutical business with particular emphasis on custom synthesis,” she explained.
“Our capabilities include full cGMP manufacturing, route selection, process and analytical development and process optimization from laboratory scale to full production, as well as delivery of safe implementation of hazardous reactions and versatile chemistry,” she added.
Isochem has also expanded exports outside its native France, particularly in North America.
Main growth drivers have been increased demand for Isochem’s custom synthesis services, along with the company’s catalog products, generic APIs and excipients.
Ms. Arboré will be accompanied in Barcelona by leaders of Isochem’s R&D, Quality, Purchasing and Project Management teams.
Yves Robin, VP R&D and Industrialization, Isochem S.A.S.
Tel: +33 1 64 99 05 49
Click on Isochem brings custom manufacturing capabilities to CPhI Worldwide for more information.
Click on ISOCHEM S.A.S to contact the company directly.